Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in ASCEND Phase III clinical trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
IPO Year: 2019
Exchange: NASDAQ
Website: satsumarx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/10/2022 | $15.00 | Mkt Perform → Outperform | SVB Leerink |
| 8/31/2022 | $16.00 | Buy | Ladenburg Thalmann |
4 - Satsuma Pharmaceuticals, Inc. (0001692830) (Issuer)
4 - Satsuma Pharmaceuticals, Inc. (0001692830) (Issuer)
4 - Satsuma Pharmaceuticals, Inc. (0001692830) (Issuer)
4 - Satsuma Pharmaceuticals, Inc. (0001692830) (Issuer)
4 - Satsuma Pharmaceuticals, Inc. (0001692830) (Issuer)
4 - Satsuma Pharmaceuticals, Inc. (0001692830) (Issuer)
4 - Satsuma Pharmaceuticals, Inc. (0001692830) (Issuer)
4 - Satsuma Pharmaceuticals, Inc. (0001692830) (Issuer)
4 - Satsuma Pharmaceuticals, Inc. (0001692830) (Issuer)
4 - Satsuma Pharmaceuticals, Inc. (0001692830) (Issuer)
DURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395), today announced that three abstracts describing efficacy and safety results from the STS101 Phase 3 efficacy trial were selected for presentation at the American Headache Society's (AHS) 65th Annual Scientific Meeting. The 2023 meeting will be held in a hybrid virtual and in-p
January 2024 PDUFA date expectedIf approved, STS101 would become the only DHE product evaluated in a randomized, placebo-controlled trial (the SUMMIT trial) against modern outcome measures recommended by both the U.S. Food and Drug Administration (FDA) and International Headache SocietyUnlike current DHE products, STS101 is designed to be easy-to-carry, quick and easy to self-administer within seconds without need for involved administration procedures and to rapidly achieve high drug plasma levels believed necessary for robust efficacy and to be below those levels associated with adverse events such as nausea and vomiting As announced on April 13, 2023 Satsuma entered into a definitive agre
SOUTH SAN FRANCISCO, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), a development-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that three abstracts highlighting STS101 were accepted at the American Academy of Neurology's (AAN) 75th Annual Meeting. The 2023 meeting will be held in a hybrid virtual and in-person format in Boston, Massachusetts from Saturday, April 22 to Thursday, April 27, 2023. Full abstracts are now available on the AAN website. Accepted Abstracts Title:Interim Analysis of Subject I
Transaction delivers immediate value and liquidity to Satsuma stockholders SNBL to acquire all outstanding shares of Satsuma for upfront cash consideration of $0.91 per share Satsuma stockholders to also receive non-tradeable CVR of up to $5.77 per share With the goal of maximizing value for stockholders, Satsuma's Board has carefully considered strategic options for Satsuma and STS101 and fully supports this transaction with SNBL SOUTH SAN FRANCISCO, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. ("Satsuma") (NASDAQ:STSA) today announced that it has entered into a definitive agreement to be acquired by Shin Nippon Biomedical L
- Announced topline results from STS101 SUMMIT Phase 3 efficacy trial that the company believes demonstrate STS101 provides differentiated, robust and sustained anti-migraine effects - - Submitted STS101 New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) in March 2023 - - Company seeking to maximize value for stockholders via strategic transaction - - ~36% workforce reduction to be implemented effective March 31, 2023 - - $52.5 million in cash, cash equivalents and marketable securities as of December 31, 2022 - SOUTH SAN FRANCISCO, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), a development-stage biopharmaceutical company
SOUTH SAN FRANCISCO, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, President and Chief Executive Officer, will deliver a company presentation during the SVB Securities Global Biopharma Conference, which is being held virtually February 14-16. Mr. Kollins will also host virtual one-on-one meetings with investors. Mr. Kollins is scheduled to present at 1:40pm ET on Thursday, February 16. A live webcast of the presentation can b
Further analysis of results from recently-completed SUMMIT Phase 3 efficacy trial of STS101 for the acute treatment of migraine shows differentiating robust and sustained antimigraine effects on clinically important secondary endpointsQualitative and quantitative primary market research conducted post-SUMMIT trial readout and incorporating updated STS101 profile consistent with SUMMIT trial results indicates headache specialists continue to have strong interest in STS101, with high prescribers of migraine therapeutics anticipating prescribing it to approximately 30% of their migraine patientsBased on communications with FDA in multiple Type C meetings and May 2022 Type B clinical pre-NDA mee
SOUTH SAN FRANCISCO, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, its President and Chief Executive Officer, will participate in a Fireside Chat at the 5th Annual Evercore ISI HealthCONx Conference, which is being held virtually November 29 - December 1. Mr. Kollins plans to discuss Satsuma's STS101 program, including the planned U.S. regulatory pathway and potential implications of recently-reported STS101 SUMMIT Phase 3 ef
STS101 was not statistically superior to placebo at two hours post-administration on the co-primary endpoints of freedom from pain and most bothersome symptom STS101 showed superiority (p<0.001) differences versus placebo on freedom from pain and most bothersome symptom at all timepoints after two hours post-administration (3, 4, 6, 12, 24 and 48 hours), as well as on multiple key secondary endpoints, including pain relief at 2 hours post-administration and all timepoints thereafterSTS101 demonstrated a favorable safety and tolerability profile, consistent with clinical trial experience to dateBased on previous interactions with the FDA, Satsuma believes results from the STS101 Phase 1 PK an
- On track to report topline results from STS101 SUMMIT Phase 3 efficacy trial in November 2022; NDA submission planned in Q1 2023 - - $64.4 million in cash, cash equivalents and marketable securities as of September 30, 2022, provides runway into second half of 2023 - SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today reported financial results for the third quarter of 2022 and summarized recent business highlights. "We are pleased to
SVB Leerink upgraded Satsuma Pharmaceuticals from Mkt Perform to Outperform and set a new price target of $15.00
Ladenburg Thalmann initiated coverage of Satsuma Pharmaceuticals with a rating of Buy and set a new price target of $16.00
Mizuho upgraded Satsuma Pharmaceuticals from Neutral to Buy and set a new price target of $15.00 from $7.00 previously
SVB Leerink reiterated coverage of Satsuma Pharmaceuticals with a rating of Market Perform and set a new price target of $5.00 from $4.00 previously
Credit Suisse resumed coverage of Satsuma Pharmaceuticals with a rating of Neutral and set a new price target of $6.50
Credit Suisse Group upgraded Satsuma Pharmaceuticals from Underperform to Neutral and set a new price target of $6.50
Mizuho resumed coverage of Satsuma Pharmaceuticals with a rating of Hold and set a new price target of $3.50
Credit Suisse upgraded Satsuma Pharmaceuticals from Underperform to Neutral and set a new price target of $6.50
DELRAY BEACH, Fla., Nov. 9, 2021 /PRNewswire/ -- Cyrano Therapeutics, a clinical stage regenerative medicine company developing a novel intranasal therapy to restore smell and flavor function, today announced that it has appointed biopharmaceutical industry veteran John Kollins to its board of directors. Kollins is currently President and Chief Executive Officer of Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine currently in Phase 3 trials.
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced the appointment of Mutya Harsch, JD to its Board of Directors, effective immediately. Ms. Harsch is a highly regarded and established pharmaceutical industry professional who brings over 20 years of legal, corporate governance, corporate transaction, and operating experience to Satsuma. She currently serves as General Counsel, Chief Legal Officer and Secretary of VYNE Therapeutic
15-12G - Satsuma Pharmaceuticals, Inc. (0001692830) (Filer)
EFFECT - Satsuma Pharmaceuticals, Inc. (0001692830) (Filer)
EFFECT - Satsuma Pharmaceuticals, Inc. (0001692830) (Filer)
EFFECT - Satsuma Pharmaceuticals, Inc. (0001692830) (Filer)
25-NSE - Satsuma Pharmaceuticals, Inc. (0001692830) (Subject)
S-8 POS - Satsuma Pharmaceuticals, Inc. (0001692830) (Filer)
S-8 POS - Satsuma Pharmaceuticals, Inc. (0001692830) (Filer)
S-8 POS - Satsuma Pharmaceuticals, Inc. (0001692830) (Filer)
S-8 POS - Satsuma Pharmaceuticals, Inc. (0001692830) (Filer)
POS AM - Satsuma Pharmaceuticals, Inc. (0001692830) (Filer)
STS101 was not statistically superior to placebo at two hours post-administration on the co-primary endpoints of freedom from pain and most bothersome symptom STS101 showed superiority (p<0.001) differences versus placebo on freedom from pain and most bothersome symptom at all timepoints after two hours post-administration (3, 4, 6, 12, 24 and 48 hours), as well as on multiple key secondary endpoints, including pain relief at 2 hours post-administration and all timepoints thereafterSTS101 demonstrated a favorable safety and tolerability profile, consistent with clinical trial experience to dateBased on previous interactions with the FDA, Satsuma believes results from the STS101 Phase 1 PK an
SC 13D/A - Satsuma Pharmaceuticals, Inc. (0001692830) (Subject)
SC 13D/A - Satsuma Pharmaceuticals, Inc. (0001692830) (Subject)
SC 13D/A - Satsuma Pharmaceuticals, Inc. (0001692830) (Subject)
SC 13D/A - Satsuma Pharmaceuticals, Inc. (0001692830) (Subject)
SC 13D/A - Satsuma Pharmaceuticals, Inc. (0001692830) (Subject)
SC 13G/A - Satsuma Pharmaceuticals, Inc. (0001692830) (Subject)
SC 13G/A - Satsuma Pharmaceuticals, Inc. (0001692830) (Subject)
SC 13G/A - Satsuma Pharmaceuticals, Inc. (0001692830) (Subject)
SC 13D/A - Satsuma Pharmaceuticals, Inc. (0001692830) (Subject)
SC 13G - Satsuma Pharmaceuticals, Inc. (0001692830) (Subject)
The Dow Jones closed higher by over 160 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Satsuma Pharmaceuticals The Trade: Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) 10% owner Shin Nippon Biomedical Laboratories Ltd acquired a total 30,477,313 shares an average price of $0.91. To acquire these shares, it cost around $27.73 million. The
January 2024 PDUFA date expected If approved, STS101 would become the only DHE product evaluated in a randomized, placebo-controlled trial (the SUMMIT trial) against modern outcome measures recommended by both the U.S. Food and Drug Administration (FDA) and International Headache Society Unlike current DHE products, STS101 is designed to be easy-to-carry, quick and easy to self-administer within seconds without need for involved administration procedures and to rapidly achieve high drug plasma levels believed necessary for robust efficacy and to be below those levels associated with adverse events such as nausea and vomiting As announced on April 13, 2023 Satsuma entered into a definiti
Upgrades Canaccord Genuity upgraded the previous rating for Sigma Lithium Corp (NASDAQ:SGML) from Speculative Buy to Buy. The current stock performance of Sigma Lithium shows a 52-week-high of $40.30 and a 52-week-low of $12.75. Moreover, at the end of the last trading period, the closing price was at $38.78. Wells Fargo upgraded the previous rating for Danaher Corp (NYSE:DHR) from Equal-Weight to Overweight. In the fourth quarter, Danaher showed an EPS of $2.87, compared to $2.69 from the year-ago quarter. The current stock performance of Danaher shows a 52-week-high of $303.81 and a 52-week-low of $234.52. Moreover, at the end of the last trading period, the closing price was at $255.75
HC Wainwright & Co. analyst Oren Livnat downgrades Satsuma Pharma (NASDAQ:STSA) from Buy to Neutral.
U.S. stocks traded slightly lower toward the end of trading. The Dow traded down 0.07% to 33,862.05 while the NASDAQ fell 0.24% to 12,093.82. The S&P 500, also fell, dropping, 0.17% to 4,130.78. Check This Out: Top 5 Health Care Stocks That May Fall Off A Cliff This Quarter Leading and Lagging Sectors Real estate shares rose by 1.1% on Monday. Meanwhile, top gainers in the sector included Altisource Asset Management Corporation (NYSE:AAMC), up 10%, and KE Holdings Inc. (NYSE:BEKE), up 6%. In trading on Monday, communication services fell by 1.5%. Top Headline State Street Corporation (NYSE:STT) reported worse-than-expected Q1 EPS and sales results. State Street reported Q1 rev
Gainers ContraFect (NASDAQ:CFRX) stock rose 317.8% to $3.76 during Monday's regular session. As of 13:30 EST, this security is trading at a volume of 93.7 million shares, making up 12124.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $5.8 million. Windtree Therapeutics (NASDAQ:WINT) shares rose 168.54% to $11.76. Trading volume for this security as of 13:30 EST is 9.3 million, which is 6427.0% of its average full-day volume over the last 100 days. The company's market cap stands at $10.6 million. Bellicum Pharmaceuticals (NASDAQ:BLCM) stock increased by 113.44% to $0.6. Bellicum Pharmaceuticals's stock is trading at a volume of
Gainers ContraFect Corporation (NASDAQ:CFRX) shares surged 213% to $2.82. Blackboxstocks Inc. (NASDAQ:BLBX) shares jumped 147.5% to $6.55 after the company announced it entered a letter of intent to merge with Evtec. Presto Automation Inc. (NASDAQ:PRST) jumped 114% to $3.00. Presto recently promoted Dan Mosher to President and Xavier Casanova to Chief Operating Officer. Windtree Therapeutics, Inc. (NASDAQ:WINT) gained 97% to $8.53. Windtree Therapeutics announced issuance of patent from European Patent Office for Dual Mechanism SERCA2a Activator. Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) jumped 94% to $1.28 after the company announced that it entered a definitive agreement to be ac
U.S. stocks traded mostly flat midway through trading, following the release of economic data. The Dow traded up 0.01% to 33,890.03 while the NASDAQ fell 0.18% to 12,101.34. The S&P 500, also fell, dropping, 0.11% to 4,133.25. Check This Out: Top 5 Health Care Stocks That May Fall Off A Cliff This Quarter Leading and Lagging Sectors Real estate shares rose by 1.6% on Monday. Meanwhile, top gainers in the sector included Altisource Asset Management Corporation (NYSE:AAMC), up 7%, and Ashford Hospitality Trust, Inc. (NYSE:AHT), up 7%. In trading on Monday, communication services fell by 1.7%. Top Headline Charles Schwab Corp (NYSE:SCHW) posted better-than-expected earnings for it